Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• The Mitogen-activated protein kinase (MAPK) pathway plays a crucial role in cell signaling and is frequently implicated in various cancers.
• Deregulation of the MAPK pathway is suspected in adrenocortical tumors (ACT), but the precise frequency of genetic alterations remains unclear.

Purpose of the Study:

• To investigate the frequency and spectrum of genetic alterations in key components of the MAPK pathway in adrenocortical tumors.
• To correlate any identified mutations with biomolecular and clinico-pathological findings in ACT patients.

Main Methods:

• Analysis of key MAPK pathway genes (BRAF, HRAS, NRAS, KRAS, EGFR) for mutations in a cohort of adrenocortical tumors.
• Detailed characterization of patients with identified mutations, including biomolecular and clinico-pathological data.

Main Results:

• One BRAF mutation (p.V600E) and four HRAS silent mutations were identified.
• No genetic alterations were detected in the NRAS, KRAS, or EGFR genes.
• The patient with the BRAF mutation underwent comprehensive biomolecular and clinico-pathological evaluation.

Conclusions:

• While MAPK signaling may be activated in adrenocortical tumors, direct genetic alterations in the analyzed MAPK pathway components appear to be infrequent.
• These findings suggest that genetic mutations within these specific MAPK pathway genes are unlikely to be a common mechanism driving adrenocortical tumor development.